Vir Biotechnology Announces Dr. Phil Pang Will Step Down as Chief Medical Officer
20 Fevereiro 2024 - 6:30PM
Business Wire
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that
Executive Vice President, and Chief Medical Officer, Phil Pang,
M.D., Ph.D., has decided to leave the company at the end of March
2024 to spend more time with his family. The Company has initiated
a search for a successor.
“Phil has served as a formidable leader at Vir, where he played
a major part in the development of sotrovimab during the peak of
the COVID-19 pandemic. With his background in infectious diseases,
he has built strong teams with a mission of targeting major unmet
needs globally, including chronic hepatitis delta, hepatitis B, and
HIV,” said Marianne De Backer, M.Sc., Ph.D., MBA, Vir’s Chief
Executive Officer. “He leaves behind a strong team of drug
developers, positioning us well for continued success. I wish him
the very best.”
“I am humbled by all that Vir has accomplished in the last seven
years, and it has been an honor to lead such a world-class team of
experts. Now, after a period of reflection, I have decided to spend
more time with my family,” said Dr. Pang. “I leave a very capable
development team that will inform the strategy and enable a smooth
transition for a new Chief Medical Officer. I am inspired by
Marianne’s vision of the future at Vir, and I look forward to
continuing to watch the company flourish.”
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc. is an immunology company focused on
powering the immune system to transform lives by treating and
preventing infectious diseases and other serious conditions,
including other viral-associated diseases. Vir has assembled two
technology platforms that are designed to stimulate and enhance the
immune system by exploiting critical observations of natural immune
processes. Its current clinical development pipeline consists of
product candidates targeting hepatitis delta and hepatitis B
viruses and human immunodeficiency virus. Vir has several
preclinical candidates in its pipeline, including those targeting
influenza A and B, COVID-19, RSV/MPV and HPV. Vir routinely posts
information that may be important to investors on its website.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “may,” “will,” “plan,” “potential,” “aim,”
“expect,” “anticipate,” “promising” and similar expressions (as
well as other words or expressions referencing future events,
conditions or circumstances) are intended to identify
forward-looking statements. These forward-looking statements are
based on Vir’s expectations and assumptions as of the date of this
press release. Forward-looking statements contained in this press
release include, but are not limited to, statements regarding
anticipated progress and the potential impact of Vir’s clinical and
preclinical development programs and expectations related thereto;
potential of, and expectations for, Vir’s Hepatitis Delta,
Hepatitis B and HIV programs, clinical trials and the expected
timing of data readouts and presentations. Results in early-stage
clinical trials may not be indicative of full results or results
from later-stage or larger-scale clinical trials and do not ensure
regulatory approval. You should not place undue reliance on these
statements. Other factors that may cause actual results to differ
from those expressed or implied in the forward-looking statements
in this press release are discussed in Vir’s filings with the US
Securities and Exchange Commission, including the section titled
“Risk Factors” contained therein. Except as required by law, Vir
assumes no obligation to update any forward-looking statements
contained herein to reflect any change in expectations, even as new
information becomes available.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240220541768/en/
Media Carly Scaduto Senior Director, Media Relations
cscaduto@vir.bio +1-314-368-5189
Investors Sasha Damouni Ellis Executive Vice President,
Chief Corporate Affairs Officer sdamouni@vir.bio
Vir Biotechnology (NASDAQ:VIR)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Vir Biotechnology (NASDAQ:VIR)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024